Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Patients with type 2 diabetes mellitus (T2DM) can have multiple comorbidities and
premature mortality due to atherosclerotic cardiovascular disease, hospitalization with heart …
premature mortality due to atherosclerotic cardiovascular disease, hospitalization with heart …
Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community
Multiple sodium glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1
receptor agonists (GLP-1RA) have been shown to impart significant cardiovascular and …
receptor agonists (GLP-1RA) have been shown to impart significant cardiovascular and …
National trends in use of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists by cardiologists and other specialties, 2015 to …
Background Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) and glucagon‐like
peptide‐1 receptor agonists (GLP‐1RAs) mitigate cardiovascular risk in individuals with type …
peptide‐1 receptor agonists (GLP‐1RAs) mitigate cardiovascular risk in individuals with type …
Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type …
D Mahtta, DJ Ramsey, MT Lee, L Chen… - Diabetes …, 2022 - Am Diabetes Assoc
OBJECTIVE There is mounting evidence regarding the cardiovascular benefits of sodium–
glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists …
glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists …
Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA …
BACKGROUND: Sodium glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-
1 receptor agonists (GLP-1 RA), and the nonsteroidal mineralocorticoid receptor antagonist …
1 receptor agonists (GLP-1 RA), and the nonsteroidal mineralocorticoid receptor antagonist …
Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial
NJ Pagidipati, AJ Nelson, LA Kaltenbach, M Leyva… - JAMA, 2023 - jamanetwork.com
Importance Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk
in adults with type 2 diabetes are underused in clinical practice. Objective To assess the …
in adults with type 2 diabetes are underused in clinical practice. Objective To assess the …
Predictors, disparities, and facility-level variation: SGLT2 inhibitor prescription among US veterans with CKD
LP Gregg, DJ Ramsey, JM Akeroyd, SA Jafry… - American Journal of …, 2023 - Elsevier
Rationale & Objective Sodium/glucose cotransporter 2 (SGLT2) inhibitors are recommended
for type 2 diabetes mellitus (T2DM) in patients with chronic kidney disease (CKD) or …
for type 2 diabetes mellitus (T2DM) in patients with chronic kidney disease (CKD) or …
Deficits and disparities in early uptake of glucagon-like peptide 1 receptor agonists and SGLT2i among medicare-insured adults following a new diagnosis of …
SJ Cromer, JC Lauffenburger, R Levin… - Diabetes Care, 2023 - Am Diabetes Assoc
OBJECTIVE To examine the association of race/ethnicity and socioeconomic deprivation
with initiation of guideline-recommended diabetes medications with cardiovascular benefit …
with initiation of guideline-recommended diabetes medications with cardiovascular benefit …
Use of sodium-glucose cotransporter 2 inhibitors and glucagonlike peptide-1 receptor agonists in patients with diabetes and cardiovascular disease in community …
MG Nanna, AA Kolkailah, C Page, ED Peterson… - JAMA …, 2023 - jamanetwork.com
Importance Recent national guidelines recommend sodium-glucose cotransporter 2
inhibitors (SGLT2i) and glucagonlike peptide-1 receptor agonists (GLP-1 RA) in patients …
inhibitors (SGLT2i) and glucagonlike peptide-1 receptor agonists (GLP-1 RA) in patients …
Understanding the place for GLP‐1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection
CR Andreasen, A Andersen, FK Knop… - Diabetes, Obesity and …, 2021 - Wiley Online Library
Since the first glucagon‐like peptide 1 (GLP‐1) receptor agonist (GLP‐1RA) was approved
in 2005 (exenatide twice daily) for type 2 diabetes (T2D), the class has developed with …
in 2005 (exenatide twice daily) for type 2 diabetes (T2D), the class has developed with …